Prima Biomed in trading halt
Tuesday, 17 November, 2009
Cancer treatment specialist pharmceutical company, Prima Biomed (ASX:PRR), has requested a trading halt on its shares until November 19 pending an announcement regarding the development its oral vaccine for cervical cancer.
Prima Biomed's flagship product is CVac, which is administered post-surgery and post-chemotherapy to delay the relapse and control the metastases of ovarian cancer.
Prima Biomed has had a stellar year on the markets. It began the year around $0.005 and rose around 3,200% to its current price.
Prima Biomed shares were last trading at 16.5c.
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
